The stock was down 18%, wiping out year-to-date gains after the biotech stopped a late-stage clinical trial of its Vyvgart drug due to lack of efficacy.
Argenx Shares Plunge After Autoimmune-Disease Trial Halt
Source: WSJ Technology
The Edge of the Cyber World See the latest
The stock was down 18%, wiping out year-to-date gains after the biotech stopped a late-stage clinical trial of its Vyvgart drug due to lack of efficacy.
Source: WSJ Technology